Jiang Huijuan, Zhang Hongzhi, Hu Xigang, Ma Jing
Department of Radiotherapy, Huaihe Hospital of Henan University, Henan, Kaifeng 475000, China.
J Cancer Res Ther. 2015 Aug;11 Suppl 1:C101-3. doi: 10.4103/0973-1482.163855.
The objective of this study is to evaluate the efficacy and toxicity reduction of Shenqi Fuzheng injection in the treatment of nonsmall cell lung cancer (NSCLC).
Through searching the PubMed, WANFANG and CNKI, we recruited clinical trials related to Shenqi Fuzheng combined with radiation in the treatment of NSCLC. We extracted the treatment effective data and radiation related toxicities data. The clinical efficacy and radiation toxicity was pooled by meta-analysis. The statistical heterogeneity was evaluated by I 2 tests.
By searching the related databases, we finally included 7 studies in this meta-analysis. The pooled results indicated that Shenqi Fuzheng injection can improve the clinical efficacy (relative risk [RR] =1.27, 95% confidence interval [CI]: 1.13-1.43), and decrease the radiation pneumonia (RR = 0.41, 95% CI: 0.26-0.46), radiation esophagitis (RR = 0.46, 95% CI: 0.37-0.59) and bone marrow suppression (RR = 0.44, 95% CI: 0.36-0.53).
Shenqi Fuzheng injection can improve the clinical efficacy and decrease the radiation toxicities in the NSCLC patients treated with radiation.
本研究旨在评估参芪扶正注射液在治疗非小细胞肺癌（NSCLC）中的疗效及降低毒性的作用。
通过检索PubMed、万方和知网，我们纳入了参芪扶正联合放疗治疗NSCLC的临床试验。我们提取了治疗有效数据和放疗相关毒性数据。通过Meta分析汇总临床疗效和放疗毒性。采用I²检验评估统计异质性。
通过检索相关数据库，我们最终在本Meta分析中纳入了7项研究。汇总结果表明，参芪扶正注射液可提高临床疗效（相对危险度[RR]=1.27，95%置信区间[CI]：1.13-1.43），并降低放射性肺炎（RR=0.41，95%CI：0.26-0.46）、放射性食管炎（RR=0.46，95%CI：0.37-0.59）和骨髓抑制（RR=0.44，95%CI：0.36-0.53）的发生率。
参芪扶正注射液可提高接受放疗的NSCLC患者的临床疗效并降低放疗毒性。
